19 November 2017 : Laboratory Research
CPNE1 Is a Useful Prognostic Marker and Is Associated with TNF Receptor-Associated Factor 2 (TRAF2) Expression in Prostate CancerJiabei Liang1AEF, Jian Zhang2EFG, Jun Ruan2EF, Yuanyuan Mi3EF, Qiang Hu2AEF*, Zhirong Wang2AEF, Bingbing Wei2ABCDEFG
Med Sci Monit 2017; 23:5504-5514
BACKGROUND: CPNE1 plays a vital role in regulating cell differentiation. The clinical and biological values of CPNE1 in prostate cancer are still unclear. The aim of this study was to investigate the clinicopathological value of CPNE1 and the association of CPNE1 with TRAF2 expression in patients with prostate cancer.
MATERIAL AND METHODS: CPNE1 expression in prostate cancer was analyzed using Gene Expression Omnibus (GEO) databases. The Cancer Genome Atlas (TCGA) dataset was used to investigate the association of CPNE1 expression with TRAF2 expression in prostate cancer. The association of CPNE1 expression with recurrence-free survival in patients was also analyzed using the TCGA dataset. Immunohistochemistry assay was performed to examine CPNE1 expression in 65 normal prostate samples and 114 prostate cancer samples. The recurrence-free survival in patients was evaluated using Kaplan-Meier curves and log-rank test. In addition, multivariate and univariate analyses of prognostic factors were investigated by Cox regression. The effect of CPNE1 on TRAF2 expression was explored in human prostate cancer DU-145 cells.
RESULTS: Our results showed that expression level of CPNE1 is higher in prostate cancer than in normal prostate tissues (P=0.006). In the GSE35988 dataset, CPNE1 expression was found to be upregulated in castration-resistant prostate cancer compared with non-castration-resistant prostate cancer (P<0.001). Furthermore, we found that CPNE1 high expression was significantly related to tumor stage, Gleason score, and poorer biochemical recurrence-free survival in prostate cancer patients. Co-expression analysis of TCGA data showed that CPNE1 is significantly associated with TRAF2 expression. CPNE1 overexpression can upregulate TRAF2 expression in prostate cancer DU-145 cells as determined by Western blotting and immunofluorescence assays.
CONCLUSIONS: Overall, our findings suggest that CPNE1 is a valuable prognostic marker for evaluating recurrence-free survival and is positively related to TRAF2 expression in prostate cancer.
Keywords: Biological Markers, Prostatic Neoplasms, Urologic Neoplasms
01 February 2024 : EditorialEditorial: Global Health Concerns as Vaccine-Preventable Infections Including SARS-CoV-2 (JN.1), Influenza, Respiratory Syncytial Virus (RSV), and Measles Continue to Rise
Med Sci Monit 2024; 30:e943911
25 Feb 2024 : Clinical ResearchComparative Efficacy of Ultrasound-Guided Cervical Fascial Infiltration versus Periarticular Administration...
Med Sci Monit In Press; DOI: 10.12659/MSM.942044
08 Feb 2024 : Clinical ResearchPredictors of Mortality in Veterans with Amyotrophic Lateral Sclerosis: Respiratory Status and Speech Disor...
Med Sci Monit In Press; DOI: 10.12659/MSM.943288
25 Feb 2024 : Clinical ResearchPatterns and Outcomes of Traumatic Suicides: A Retrospective Study of 132 Patients Admitted to a Turkish Me...
Med Sci Monit In Press; DOI: 10.12659/MSM.943505
Most Viewed Current Articles
16 May 2023 : Clinical ResearchElectrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review articleVaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical ResearchPrevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels
Med Sci Monit 2022; 28:e937990